Trends In Prostate Cancer In The United States

Trends In Prostate Cancer In The United States

The ASUP of NOS treatment has increased from 32.3 in 2010 to 36.8 in 2015 (P). In conclusion, ASUR and ASUP for prostate cancer treatments, including NOS treatment, had changed during. Their trends appeared to differ by cancer risk-group, age, race/ethnicity, Gleason score and socioeconomic factors. Patient summary: We assessed how the incidence of ultimately fatal prostate cancer (PCa) changed over time. We found that the incidence of fatal PCa declined by 50 since the introduction of prostate-specific antigen testing and advances in treatment options; however, incidence rates among younger men remained relatively stable, and younger black men exhibited a 4.2-fold higher risk for fatal disease compared with white men. In the United States, prostate cancer is the most commonly diagnosed non–skin cancer and the second leading cause of cancer death. The American Cancer Society estimates that 241 740 American men will be diagnosed with the disease and 28 170 men will die of it in 2012.